Loncar argues that, unlike companies that
abuse their prerogative to dictate
whatever list prices they want in the U.S., Novartis has actually pulled off the
kind of scientific innovation that the biopharma industry claims as its beating heart.
But
whatever you think
of the merits
of the particular lawsuit against Gawker, critics warn that this
kind of arrangement — where a wealthy person funds third - party lawsuits against a common foe — is ripe for
abuse.